The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Should COVID-19 vaccination be postponed after acute myeloid leukemia therapy?
Sabine Haggenburg
January 6, 2022
During the 63rd ASH Annual Meeting and Exposition, Know AML spoke with Sabine Haggenburg, Amsterdam UMC, Amsterdam, NL. We asked, Should COVID-19 vaccination be postponed after acute myeloid leukemia therapy?
Haggenburg begins by discussing COVID-19 risks to acute myeloid leukemia patients, and the responses to vaccinations that have been observed so far. However, she highlights that vaccination does not protect patients taking hypomethylating agents (HMAs), such as azacitidine and decitabine.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
